title: Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
authors.forename: Zaher K
authors.initials: ZK
authors.lastname: Otrock
authors.forename: Rami A
authors.initials: RA
authors.lastname: Mahfouz
authors.forename: Zahera
authors.initials: Z
authors.lastname: Fahed
authors.forename: Fadi S
authors.initials: FS
authors.lastname: Farhat
authors.forename: Azzam
authors.initials: A
authors.lastname: Ziade
authors.forename: Fadi
authors.initials: F
authors.lastname: Nasr
authors.forename: Nader
authors.initials: N
authors.lastname: Kassem
authors.forename: Miguel R
authors.initials: MR
authors.lastname: Abboud
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib